Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum Sells 4,000 Shares

Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 309,565 shares in the company, valued at $2,786,085. This trade represents a 1.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Rhonda Farnum also recently made the following trade(s):

• On Monday, November 11th, Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock. The stock was sold at an average price of $9.00, for a total value of $36,000.00.

Theravance Biopharma Trading Up 3.3 %

Shares of TBPH stock traded up $0.31 on Thursday, hitting $9.67. 173,993 shares of the stock were exchanged, compared to its average volume of 181,157. The firm’s 50 day moving average is $9.45 and its two-hundred day moving average is $8.90. Theravance Biopharma, Inc. has a one year low of $7.44 and a one year high of $10.44. The firm has a market capitalization of $475.47 million, a PE ratio of -9.57 and a beta of 0.21.

Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16). The business had revenue of $16.87 million for the quarter, compared to the consensus estimate of $16.11 million. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. During the same quarter in the prior year, the business earned ($0.17) EPS. On average, sell-side analysts expect that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. American Century Companies Inc. boosted its holdings in shares of Theravance Biopharma by 11.7% in the second quarter. American Century Companies Inc. now owns 57,611 shares of the biopharmaceutical company’s stock worth $489,000 after acquiring an additional 6,026 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Theravance Biopharma by 38.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 330,181 shares of the biopharmaceutical company’s stock valued at $2,800,000 after purchasing an additional 91,679 shares during the period. Hsbc Holdings PLC purchased a new stake in Theravance Biopharma during the 2nd quarter worth about $108,000. XTX Topco Ltd bought a new position in Theravance Biopharma in the 2nd quarter worth about $129,000. Finally, Bank of Montreal Can grew its holdings in Theravance Biopharma by 141.0% during the 2nd quarter. Bank of Montreal Can now owns 160,138 shares of the biopharmaceutical company’s stock valued at $1,414,000 after buying an additional 93,702 shares in the last quarter. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.